Consensus Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
7.14 ^USD	+0.14%		+4.39%	+5.78%

Mar. 18	Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	MT
Mar. 18	Fulcrum Therapeutics, Inc. Announces Executive Changes	CI

Evolution of the average Target Price on Fulcrum Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6cda263c88d71840f862a.lLFmK_SX3gwyblWlmxvm22P-kHi3ItSAHsoqLRSec74.pf4eX43h6Vt1GQ3m6V_R6ifM-w3nUZXJdItje13VCerg91RfhsS9R349Jg~d692378aa44b4b234c7f41c61cf573bd

Analyst Recommendations on Fulcrum Therapeutics, Inc.

Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $15 From $13, Maintains Overweight Rating	Feb. 28	MT
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $6 From $5, Maintains Neutral Rating	Jan. 25	MT
HC Wainwright Upgrades Fulcrum Therapeutics to Buy From Neutral, Adjusts Price Target to $14 From $5	23-08-23	MT
Stifel Upgrades Fulcrum Therapeutics to Buy From Hold, Raises Price Target to $11 From $4	23-08-22	MT
Oppenheimer Adjusts Fulcrum Therapeutics Price Target to $16 From $20, Maintains Outperform Rating	23-05-16	MT
HC Wainwright Adjusts Price Target on Fulcrum Therapeutics to $5 From $6, Maintains Neutral Rating	23-05-16	MT
Stifel Lowers Fulcrum Therapeutics' Price Target to $4 From $6, Hold Rating Kept	23-05-15	MT
Goldman Sachs Downgrades Fulcrum Therapeutics to Neutral From Buy, Adjusts Price Target to $3 From $9	23-05-04	MT
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $9 From $17, Maintains Buy Rating	23-03-13	MT
Stifel Downgrades Fulcrum Therapeutics to Hold From Buy, Adjusts Price Target to $6 From $35	23-03-10	MT
Morgan Stanley Adjusts Price Target on Fulcrum Therapeutics to $7 From $8, Maintains Equalweight Rating	23-03-10	MT
Credit Suisse Downgrades Fulcrum Therapeutics to Neutral From Outperform, Adjusts Price Target to $8 From $11	23-03-10	MT
HC Wainwright Downgrades Fulcrum Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $20	23-03-10	MT
Morgan Stanley Downgrades Fulcrum Therapeutics to Equalweight From Overweight, Adjusts Price Target to $8 From $27	23-02-28	MT
Oppenheimer Adjusts Fulcrum Therapeutics' Price Target to $20 From $26, Maintains Outperform Rating	23-02-27	MT
Credit Suisse Lowers Fulcrum Therapeutics' PT to $11 From $19, Says FTX-6058 Clinical Hold Introduces Near-Term Uncertainty; Keeps Outperform Rating	23-02-27	MT
Morgan Stanley Adjusts Price Target on Fulcrum Therapeutics to $27 From $26, Maintains Overweight Rating	23-01-24	MT
Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $21 From $18, Maintains Overweight Rating	23-01-23	MT
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $17 From $11, Maintains Buy Rating	23-01-19	MT
Goldman Sachs Starts Fulcrum Therapeutics at Buy With $11	22-11-15	MT
Morgan Stanley Adjusts Price Target on Fulcrum Therapeutics to $26 From $25, Maintains Overweight Rating	22-11-14	MT
Credit Suisse Adjusts Fulcrum Therapeutics' Price Target to $19 From $22, Keeps Outperform Rating	22-11-09	MT
Oppenheimer Adjusts Fulcrum Therapeutics Price Target to $30 From $33, Maintains Outperform Rating	22-11-09	MT
Stifel Lowers Price Target on Fulcrum Therapeutics to $35 From $43, Maintains Buy Rating	22-10-20	MT
HC Wainwright Adjusts Fulcrum Therapeutics' Price Target to $20 From $40, Reiterates Buy Rating	22-06-13	MT